阿斯特拉加勒斯的多糖阻碍了宫癌通过向NR3C2和激活SLC40A1来阻止免疫逃生
Wenzhi Liu1, Lu Zhang2, Yixin Wang3
1Medical Education Department, Changzhou Hospital of Traditional Chinese Medicine, Changzhou, 213003, Jiangsu, PR China.
阿斯特拉加卢斯多糖 (APS) 通过向NR3C2和激活SLC40A1.1.2来抑制宫癌免疫逃生. 这种机制增强了CD8+T细胞的功能,为宫癌提供了潜在的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 宫癌 (CC) 呈现出免疫逃逸,阻碍有效治疗.
- 阿斯特拉加勒斯多糖 (APS) 在癌症预防和免疫调节方面显示出潜力.
- 了解APS在CC免疫逃避中的分子机制至关重要.
研究的目的:
- 调查APS抑制子宫癌免疫逃逸的机制.
- 识别和验证参与CC免疫逃避的APS下游目标.
- 为了阐明CC中APS,NR3C2和SLC40A1的调节途径.
主要方法:
- 在体外评估APS对CC细胞活力 (HeLa,SiHa) 和免疫逃避的影响.
- 使用U14细胞诱导的皮下瘤模型进行体内研究,以评估APS疗效.
- 生物信息分析用于选APS目标,验证NR3C2调节,并识别NR3C2下游分子.
- 在体内和体外验证NR3C2和SLC40A1在免疫逃逸中的作用.
主要成果:
- 在CC细胞系和体内模型中,APS治疗抑制了免疫逃逸.
- APS激活了NR3C2的表达,这反过来又促进了SLC40A1的表达.
- 抑制NR3C2逆转了APS的抗免疫逃生效应.
- 提高SLC40A1的调节增强了APS在CC免疫逃逸上的抑制作用.
结论:
- 在宫癌中,APS有效地抑制了免疫逃生.
- 该机制涉及向NR3C2,从而激活SLC40A1.1.
- 这种由APS激活的NR3C2-SLC40A1通路增强了CD8+T细胞功能,为CC提供了新的治疗途径.
更多相关视频
09:03Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
Published on: January 26, 2024
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
相关概念视频
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Treatment Resistant Cancers
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Treatment Resistent Cancers
